Tags

Type your tag names separated by a space and hit enter

Characteristics of patients with hepatitis C virus with and without GB virus C/hepatitis G virus co-infection and efficacy of interferon alfa.
Hepatology. 1998 May; 27(5):1388-93.Hep

Abstract

GB virus C/hepatitis G virus (GBV-C/HGV) infection seems to be common among patients with hepatitis C virus (HCV) infection. We studied retrospectively the proportions of patients with GBV-C/HGV RNA and antibodies to the GBV-C/HGV second envelope protein (anti-E2) among 149 subjects with chronic hepatitis C who had received interferon alfa. The clinical characteristics of patients with GBV-C/HGV RNA or anti-E2 were examined, as was the efficacy of the treatment. Stored serum specimens were tested for GBV-C/HGV RNA by the reverse transcription polymerase chain reaction and for anti-E2 by an enzyme-linked immunosorbent assay. Of the 149 patients before therapy, 8 (5%) had GBV-C/HGV RNA only, 72 (48%) had anti-E2 only, and 4 (3%) had both. The mean age of patients with GBV-C/HGV RNA (some with anti-E2) was significantly less than that of patients with anti-E2 only. Results of laboratory and histological evaluations were not different depending on the presence of GBV-C/HGV RNA or anti-E2. The GBV-C/HGV RNA titer decreased during therapy in all 12 patients with GBV-C/HGV RNA; only 4, with a low titer before therapy and with anti-E2 detected at some time, had sustained clearance of GBV-C/HGV. Our results suggested that half of the patients with chronic hepatitis C had been exposed to GBV-C/HGV, but in almost all, the virus had been cleared; also, even chronic GBV-C/HGV infection did not affect the severity of the disease arising from HCV. Interferon alfa treatment was sometimes effective against GBV-C/HGV, and anti-E2 may be associated with clearance of GBV-C/HGV.

Authors+Show Affiliations

Department of Public Health, Osaka City University Medical School, Osaka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9581696

Citation

Enomoto, M, et al. "Characteristics of Patients With Hepatitis C Virus With and Without GB Virus C/hepatitis G Virus Co-infection and Efficacy of Interferon Alfa." Hepatology (Baltimore, Md.), vol. 27, no. 5, 1998, pp. 1388-93.
Enomoto M, Nishiguchi S, Fukuda K, et al. Characteristics of patients with hepatitis C virus with and without GB virus C/hepatitis G virus co-infection and efficacy of interferon alfa. Hepatology. 1998;27(5):1388-93.
Enomoto, M., Nishiguchi, S., Fukuda, K., Kuroki, T., Tanaka, M., Otani, S., Ogami, M., & Monna, T. (1998). Characteristics of patients with hepatitis C virus with and without GB virus C/hepatitis G virus co-infection and efficacy of interferon alfa. Hepatology (Baltimore, Md.), 27(5), 1388-93.
Enomoto M, et al. Characteristics of Patients With Hepatitis C Virus With and Without GB Virus C/hepatitis G Virus Co-infection and Efficacy of Interferon Alfa. Hepatology. 1998;27(5):1388-93. PubMed PMID: 9581696.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characteristics of patients with hepatitis C virus with and without GB virus C/hepatitis G virus co-infection and efficacy of interferon alfa. AU - Enomoto,M, AU - Nishiguchi,S, AU - Fukuda,K, AU - Kuroki,T, AU - Tanaka,M, AU - Otani,S, AU - Ogami,M, AU - Monna,T, PY - 1998/5/15/pubmed PY - 1998/5/15/medline PY - 1998/5/15/entrez SP - 1388 EP - 93 JF - Hepatology (Baltimore, Md.) JO - Hepatology VL - 27 IS - 5 N2 - GB virus C/hepatitis G virus (GBV-C/HGV) infection seems to be common among patients with hepatitis C virus (HCV) infection. We studied retrospectively the proportions of patients with GBV-C/HGV RNA and antibodies to the GBV-C/HGV second envelope protein (anti-E2) among 149 subjects with chronic hepatitis C who had received interferon alfa. The clinical characteristics of patients with GBV-C/HGV RNA or anti-E2 were examined, as was the efficacy of the treatment. Stored serum specimens were tested for GBV-C/HGV RNA by the reverse transcription polymerase chain reaction and for anti-E2 by an enzyme-linked immunosorbent assay. Of the 149 patients before therapy, 8 (5%) had GBV-C/HGV RNA only, 72 (48%) had anti-E2 only, and 4 (3%) had both. The mean age of patients with GBV-C/HGV RNA (some with anti-E2) was significantly less than that of patients with anti-E2 only. Results of laboratory and histological evaluations were not different depending on the presence of GBV-C/HGV RNA or anti-E2. The GBV-C/HGV RNA titer decreased during therapy in all 12 patients with GBV-C/HGV RNA; only 4, with a low titer before therapy and with anti-E2 detected at some time, had sustained clearance of GBV-C/HGV. Our results suggested that half of the patients with chronic hepatitis C had been exposed to GBV-C/HGV, but in almost all, the virus had been cleared; also, even chronic GBV-C/HGV infection did not affect the severity of the disease arising from HCV. Interferon alfa treatment was sometimes effective against GBV-C/HGV, and anti-E2 may be associated with clearance of GBV-C/HGV. SN - 0270-9139 UR - https://www.unboundmedicine.com/medline/citation/9581696/Characteristics_of_patients_with_hepatitis_C_virus_with_and_without_GB_virus_C/hepatitis_G_virus_co_infection_and_efficacy_of_interferon_alfa_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0270913998002031 DB - PRIME DP - Unbound Medicine ER -